Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yonghe Medical Group Co's revenue for the
six
months ended in Jun. 2026 was €125.6 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €240.4 Mil.
Yonghe Medical Group Co's Revenue per Share for the
six
months ended in Jun. 2026 was €0.25.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.48.
Warning Sign:
Yonghe Medical Group Co Ltd revenue per share has been in decline for the last 5 years.
During the past 8 years, Yonghe Medical Group Co's highest 3-Year average Revenue per Share Growth Rate was 44.60% per year. The lowest was -14.60% per year. And the median was 5.50% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Yonghe Medical Group Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yonghe Medical Group Co Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yonghe Medical Group Co's Revenue distribution charts can be found below:
* The bar in red indicates where Yonghe Medical Group Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €240.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yonghe Medical Group Co (FRA:L97) has a Revenue of €240.4 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Yonghe Medical Group Co and its competitors.
Is Yonghe Medical Group Co's Revenue too high?
Yonghe Medical Group Co's current Revenue is €240.4 Mil. Overall, Yonghe Medical Group Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Yonghe Medical Group Co's Revenue compare to HCA and THC?
Yonghe Medical Group Co's Revenue of €240.4 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Yonghe Medical Group Co and its competitors. Yonghe Medical Group Co's current Revenue is €240.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yonghe Medical Group Co stock overvalued right now?
Yonghe Medical Group Co (FRA:L97) has a current Revenue of €240.4 Mil. The stock's GF Value™ is €0.21, compared to a current price of €0.26 — trading 22.9% above its estimated fair value. The current Revenue is €240.4 Mil. Yonghe Medical Group Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Yonghe Medical Group Co (FRA:L97), the current Revenue is €240.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yonghe Medical Group Co (FRA:L97) Overvalued in 2026?
Based on GuruFocus' analysis, Yonghe Medical Group Co stock appears to be overvalued.
The current stock price of €0.26 is trading 22.9% above its estimated GF Value™ of €0.21.
Key valuation signals for FRA:L97:
Revenue: €240.4 Mil
GF Value™: €0.21 vs. price of €0.26 (22.9% above fair value)
No single metric tells the full story. See the FRA:L97 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yonghe Medical Group Co Ltd is a medical group in China that specializes in providing hair-related healthcare services. The company is principally engaged in the provision of hair transplant services. The company generated the majority of its revenue from hair transplant services. The company offers one-stop hair-related healthcare services covering hair transplants, medical hair care, routine hair restoration, and other ancillary services.
84GF Score
Get the complete analysis for FRA:L97
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L97 has been successfully added to your 
